Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential counterparties for a merger or a reverse takeover (RTO), is progressing according to plan and is expected to be completed during the first quarter of 2026.
As previously announced in the press release dated 4 December 2025, the Company’s Board of Directors has decided to initiate a strategic review that includes an exploration of possible strategic alternatives, such as identifying potential…